Navigation Links
Stem Cell Therapy to Skyrocket by 2017
Date:9/13/2007

Although still in its infancy, stem cell therapy market to grow rapidly

over next decade

WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group (MRG) has conducted a detailed analysis of the stem cell therapy market in its US Markets for Stem Cell Therapies 2007 report. The analysis reveals that although the market for stem cell therapies is in its infancy, it will grow rapidly as products are approved in the US. Today, only two products are on the market, but by 2017, almost 90 are expected to be available.

Stem cells have regenerative capabilities, and promise lasting treatments for chronic disorders and potential cures for currently 'incurable' diseases. In 2007, the US stem cell therapies market earned over $25 million in revenues, with only two orthopedic products available in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity. Aside from these two products, the development of the US market for stem cell therapies is largely dependent on the success of clinical trials, regulatory approval, and public acceptance. The first products in the cardiovascular, diabetes, neurological, and tissue and organ stem cell therapy markets are expected to enter the market between 2009 and 2013. The entry of these products will open up a new realm of treatable disorders, offering hope to patients and vast market potential.

"This market has almost everything going its way", says Chris Schutz, senior analyst at MRG. "The big question mark however is the political and public support. The prevalence of potentially treatable disorders, unmet medical needs, rising health care costs, growth in the aging population, and the success of the first stem cell therapy products are all factors that will drive this market upward through 2017."

The US Markets for Stem Cell Therapies 2007 report includes coverage of companies offering or developing products for the stem cell therapy market, including Aas
'/>"/>

SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. TomoTherapy opens technical training center
4. TomoTherapy raises $223 million in IPO
5. TomoTherapy revises IPO money target
6. Stem cell therapy shows visionary promise
7. Hospital named for Madame Curie installs TomoTherapy system
8. TomoTherapy files registration statement for IPO
9. TomoTherapy to sell medical devices in India
10. TomoTherapy sees sustained market advantage
11. Mirus granted European patent for gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... has named Todd Creech as Chief Financial Officer and ... Creech has been fulfilling both positions as a consultant ... http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) "Todd comes to ... leadership roles and has demonstrated great success in helping ...
... Even with radical advances in medicine and technology ... penile extender system is still the most effective ... QuickExtenderPro.com, the leading provider of penis extender ... With the emergence of the penile extender, procedures such ...
... EXTON, Pa., Feb. 11, 2011 ViroPharma Incorporated (Nasdaq: ... chief executive officer of ViroPharma, will present at the Leerink ... ET on Thursday, February 17, 2011.  The conference is being ... ViroPharma,s presentations will be webcast live for investors through ...
Cached Biology Technology:Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 2Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 3QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery 2ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference 2
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
(Date:4/18/2014)... and comet impacts can cause widespread ecological havoc, killing ... scales. But new research from Brown University shows that ... at the time of an impact. , A research ... fragments of leaves and preserved organic compounds lodged inside ... The material could provide a snapshot of environmental conditions ...
(Date:4/17/2014)... chili peppers. Information about archaeological remains of ancient chili ... appearance of words for chili peppers in ancient dialects ... highlight the value of multi-proxy data analysis. Their results ... papers presented in a special feature issue of the ... on plant and animal domestication edited by Dolores Piperno, ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Earthwatch met in Panama from Mar. 1-5 to present mid-term ... to identify and respond to the impacts of climate change. ... global team of bank employees ,climate champions, in ... program of its kind has so far: , Found ...
... $10.2 million commitment from the Robertson Foundation to create ... Duke Medicine,s pioneering cell therapy research and treatment programs ... and brain injuries suffered at birth. In making the ... Duke University, and Chief Executive Officer for Duke University ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... field, ethicists, legislators, the media and the public. ... are open to journalists and registration is free to ...
Cached Biology News:HSBC Climate Partnership yields initial research findings 2HSBC Climate Partnership yields initial research findings 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3ESHRE Annual Meeting, June 27-30 in Rome 2
... Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the fusion ... immunized (BALB/c X C57BL/6)F1 (CbyB6F1) ... mouse myeloma cellline. ...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: